Millions of patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and obesity face renewed clarity regarding psychiatric safety, according to a systematic review published in the journal Cureus by Quadir et al. Researchers evaluating 11 primary studies representing over 4.9 million patients found no consistent class-wide increase in neuropsychiatric risks such as depression, suicidal ideation, or psychiatric hospitalization.
Evaluating GLP-1 Psychiatric Safety Across 4.9 Million Patients
Post-marketing reports of suicidal ideation and worsening depressive episodes initially prompted intense regulatory scrutiny regarding medications like semaglutide and liraglutide. However, the U.S. Food and Drug Administration previously investigated this safety signal and concluded that available evidence failed to establish a causal link between GLP-1 receptor agonists and suicidal behavior. To test these findings further, Quadir et al. analyzed studies published between 2021 and May 2026 across PubMed, Google Scholar, and ScienceDirect, adhering to PRISMA guidelines.
Out of 617 initial records, researchers screened 542 abstracts and fully assessed 181 reports before quality appraisals left 11 observational studies for final synthesis. Ten of these investigations were cohort studies, while one was a cross-sectional study. According to the review authors, nine of the ten cohort studies observed no elevated neuropsychiatric risk, frequently pointing toward neutral or even protective associations when compared against active antidiabetic treatments.
Comparing Cohort Findings: Lower Risks and Divergent Data
Significant variations emerged when comparing large-scale registry data against specialized obesity cohorts. Research evaluated by Quadir and his team, utilizing a multinational registry, demonstrated that taking GLP-1RAs correlated with a decrease of roughly 17% in the combined incidence of nonfatal self-harm and suicide-related mortality. Another large study reported roughly a 10% lower risk of suicidal ideation, suicide attempt, or intentional self-harm among treated populations.
When Stanislaus et al. directly contrasted different medication types, they found no elevated neuropsychiatric hazard relative to sodium-glucose cotransporter-2 (SGLT-2) inhibitors, alongside a decreased risk when compared against dipeptidyl peptidase-4 (DPP-4) inhibitors. Conversely, an obesity-focused cohort led by Kornelius et al. produced divergent results, reporting nearly three times the risk of major depressive disorder and about twice the risk of anxiety and suicidal ideation or attempts among GLP-1RA users. The review notes that greater clinical scrutiny in specialized weight-management clinics likely contributes to this increased diagnostic capture, though formal surveillance bias testing was not performed.
Exploring Antidepressant Potential and Psychometric Measures
The presence of GLP-1 receptors in brain regions regulating both metabolism and mood has fueled scientific interest in possible neuroprotective or antidepressant effects. Despite this biological plausibility, direct psychometric evidence remains sparse. Only a single cross-sectional study included in the review utilized validated continuous mood scales to measure mental health outcomes directly.
Witaszek et al. administered the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) to 1,105 adult women. The analysis revealed that semaglutide users had modestly lower depression and anxiety scores than the broader sample, with both differences achieving statistical significance. Furthermore, Taipale et al. reported that semaglutide and liraglutide were associated with reduced psychiatric worsening in patients diagnosed with pre-existing depression or anxiety, alongside a 28% lower risk of hospitalization for a psychiatric cause or self-harm for semaglutide users.
Did You Know? While millions of patients rely on GLP-1 receptor agonists like semaglutide, tirzepatide—a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist—also met inclusion criteria in the recent Cureus review.
Frequently Asked Questions
Do GLP-1 drugs increase the risk of depression or suicide?
According to the systematic review by Quadir et al. in Cureus, observational cohort evidence covering over 4.9 million patients shows no consistent class-wide increase in neuropsychiatric risks. Most studies found neutral or protective associations.
Can semaglutide help reduce anxiety and depression symptoms?
Limited psychometric evidence from a cross-sectional study by Witaszek et al. involving 1,105 adult women found that semaglutide users exhibited modestly lower depression and anxiety scores on validated scales. However, researchers emphasize that more prospective, scale-based trials are required to confirm antidepressant efficacy.
Why did one obesity study show higher psychiatric risks?
Kornelius et al. reported higher risks of major depressive disorder and anxiety in an obesity-focused cohort. Review authors note that heightened clinical scrutiny and surveillance bias in specialized weight-management environments may partially explain these elevated diagnostic rates.
Join the Conversation
What are your thoughts on the evolving data surrounding metabolic therapies and mental health? Share your perspective in the comments below, explore our latest health news, or subscribe to our newsletter for ongoing updates on clinical research.
Worth a look